# DESCRIPTION

## TECHNICAL FIELD

- relate to methods and pharmaceutical compositions

## BACKGROUND ART

- suggest cortico-hippocampal hyperactivity in epilepsy
- suggest cortico-hippocampal hyperactivity in MCI
- suggest cortico-hippocampal hyperactivity in AD
- limitations of anti-epileptic drugs
- limitations of AD treatments
- gene expression patterns in MCI
- metabolic changes in epilepsy

## SUMMARY OF INVENTION

- discover DHODH enzyme as regulator of neuronal excitability
- inhibit DHODH enzyme to reduce cortico-hippocampal hyperactivity
- use of teriflunomide as DHODH inhibitor
- use of siRNA or shRNA to knockdown DHODH
- method for preventing or treating neurodegenerative diseases
- DHODH inhibition reduces firing rates
- method for preventing or treating diseases with cortico-hippocampal hyperactivity
- pharmaceutical composition for preventing or treating diseases
- kit for co-administration of pharmaceutical compositions

## DETAILED DESCRIPTION

- define cortico-hippocampal hyperactivity
- describe neuronal excitability and synaptic transmission
- introduce active agent capable of reducing DHODH enzyme activity
- describe nucleic acid molecule capable of reducing DHODH gene expression
- introduce siRNA molecules
- describe shRNA molecules
- introduce artificial siRNA or shRNA molecule
- describe human DHODH enzyme
- introduce sequence identity of siRNA or shRNA molecule
- describe specific siRNA or shRNA molecule
- introduce vector comprising nucleic acid molecule
- describe modified virus derived from virus
- introduce lentiviral-based shRNA delivery system
- describe small molecule capable of reducing DHODH enzyme activity
- introduce DHODH inhibitors
- describe pharmaceutically acceptable salts of DHODH inhibitor
- introduce acid addition salts
- describe base addition salts
- introduce cationic lipid or mixture of cationic lipids
- describe neutral lipids
- introduce pharmaceutically acceptable salts of DHODH inhibitor formed by conventional means
- describe administration of active agent alone or with pyrimidine nucleobase
- define pyrimidine nucleobase
- describe de novo pyrimidine synthesis
- introduce intermediate in de novo synthesis of pyrimidine nucleobases
- describe method comprising administering combination of agents
- describe method comprising administering solely active agent
- describe method for treating neurodegenerative disease or disorder
- define treating
- define preventing
- define therapeutically effective amount
- describe administration routes
- describe method for treating neurodegenerative diseases
- specify active agent and pyrimidine nucleobase
- describe pharmaceutical composition
- describe active agent
- describe pyrimidine nucleobase
- describe diseases associated with cortico-hippocampal hyperactivity
- describe pharmaceutical composition with active agent and pyrimidine nucleobase
- describe preparation of pharmaceutical composition
- describe formulation for parenteral administration
- describe formulation for oral administration
- describe formulation for inhalation
- describe kit for co-administration
- describe active agent in kit
- describe pyrimidine nucleobase in kit
- describe administration routes for kit
- postulate intrathecal administration efficiency
- describe method for treating multiple sclerosis
- describe active agent for treating multiple sclerosis
- describe pharmaceutical composition for treating multiple sclerosis
- describe preparation of pharmaceutical composition for treating multiple sclerosis
- describe formulation for intrathecal administration
- describe active agent for use in treating multiple sclerosis
- describe pharmaceutical composition for use in treating multiple sclerosis
- describe kit for treating multiple sclerosis
- describe active agent in kit for treating multiple sclerosis
- describe pyrimidine nucleobase in kit for treating multiple sclerosis
- describe administration routes for kit for treating multiple sclerosis
- describe method for preventing multiple sclerosis
- describe active agent for preventing multiple sclerosis
- describe pharmaceutical composition for preventing multiple sclerosis
- describe kit for preventing multiple sclerosis

## EXAMPLES

### Example 1. DHODH is a Potential Metabolic Target for Epilepsy and MCI

- apply metabolic transformation algorithm
- conduct in silico knockout screen
- identify DHODH as potential target

### Example 2. DHODH Inhibition Induces a Stable Reduction of Mean Firing Rates in Hippocampal Networks

- test effect of DHODH inhibitor on neuronal activity
- analyze effect of DHODH inhibition on mean firing rate

### Example 3. DHODH-Mediated Inhibition of Firing Rates is not Dependent on De Novo Pyrimidine Synthesis

- test effect of uridine on DHODH inhibition

### Example 4. DHODH Inhibition Induces a Reduction in Intrinsic Excitability

- analyze effect of DHODH inhibition on intrinsic excitability

### Example 5. DHODH Inhibition Induces an Increase in the Inhibition-Excitation Ratio

- analyze effect of DHODH inhibition on excitatory and inhibitory conductance
- calculate inhibition-excitation ratio

### Example 6. DHODH Inhibition Induces a Decrease in Excitatory Quantal Amplitude

- analyze effect of DHODH inhibition on mEPSC amplitude

### Example 7. DHODH Inhibition Induces an Increase in Excitability of Fast-Spiking PV Interneurons

- analyze effect of DHODH inhibition on PV cell excitability
- identify differential regulation of PV cells

### Example 8. DHODH Inhibition does not Impair Neuronal Homeostatic System

- test effect of DHODH inhibition on homeostatic compensation
- analyze effect of baclofen on MFR

### Example 9. DHODH Inhibition Reduces Behavioral Seizure Duration in Pilocarpine Model for TLE

- describe pilocarpine model of TLE
- inject teriflunomide or vehicle in mice
- induce seizures with pilocarpine
- measure behavioral seizure duration
- analyze effect of teriflunomide on seizure duration
- discuss potential therapeutic benefit
- describe features of pilocarpine model
- discuss correlation of seizure duration with hippocampal pathology

